News Background

Oxford, UK – 08 June 2015. OGT, The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure® Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders  (DDD) study data — which successfully identified new areas of the genome responsible for developmental disorders.1, 2 OGT has used this data, together with the latest updates from ClinGen*, to deliver the most advanced, high-resolution developmental disorder arrays currently available.

OGT has optimised the arrays via a proprietary probe design algorithm and experimental validation, enabling the selection of highly-targeted, specific probes throughout the genome. Using an informed, sophisticated approach to array design, more of these optimised probes have been placed in regions of the genome that are most likely to detect a biologically relevant aberration. The result of this careful design procedure means that regions with the highest priority are covered at exon-level resolution on the arrays, enabling single-exon CNV detection in up to 502 prioritised genes of interest.

James Clough, Executive Vice President Commercial at OGT commented, “Through combining our superior array design capabilities with the latest research-led gene content, we are proud to offer our customers the most advanced array design available for accurately and easily identifying the causal aberrations underlying developmental delay. These new products underline OGT’s long-standing commitment to providing cytogenetics researchers with the latest tools to further understand developmental disorders”.

Providing straightforward analysis, all CytoSure arrays come with OGT’s renowned Cytosure Interpret Software and full on-site training, streamlining data analysis and interpretation. Innovative features enable the automation of data analysis workflows, minimising user intervention and maximising both consistency and speed of interpretation.

 

References

  1. Large-scale discovery of novel genetic causes of developmental disorders. The Deciphering Developmental Disorders Study. Fitzgerald, T.W. et al, Nature 519, 223–228 (12 March 2015)
  2. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Fitzgerald, T.W. et al,  The Lancet 385, No. 9975, p1305–1314, (4 April 2015)

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

 

For more information on the Company, please visit our website at ogt.com

 

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

 

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

You might also be interested in

Sysmex and the Kobe City Eye Hospital sign collaboration agreement Listing Image

Sysmex and the Kobe City Eye Hospital sign collaboration agreement

05 Mar 2020

Reinforcing collaboration toward the realisation of genomic medicine in the area of ophthalmic disorders.

Read
NHS study confirms higher reporting rate for OGT's CytoSure v3 array Listing Image

NHS study confirms higher reporting rate for OGT's CytoSure v3 array

22 Jul 2020

Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.

Read
OGT launches breakthrough NGS panel for constitutional cytogenetics Listing Image

OGT launches breakthrough NGS panel for constitutional cytogenetics

30 Jan 2020

Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter